Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact

Heart failure (HF) is an increasingly common syndrome associated with high mortality and economic burden, and there has been a paucity of new pharmacotherapies that improve outcomes over the past decade. However, recent data from a large, randomized controlled trial compared the novel agent LCZ696, a dual acting angiotensin receptor blocker and neprilysin inhibitor (ARNi), to the well-established angiotensin-converting enzyme (ACE) inhibitor enalapril and found significant reduction in mortality among the chronic, reduced ejection fraction HF population.

Source: Journal of Cardiac Failure - July 21, 2015 Category: Cardiology Authors: Jonathan Buggey, Robert J. Mentz, Adam D. DeVore, Eric J. Velazquez Source Type: research